The combination of venetoclax, a Bcl-2 homology domain 3 (BH3) mimetic and selective BCL-2 inhibitor, with azacitidine, a hypomethylating agent, shows promising results as a novel clinical strategy to improve AML therapy [10,11]. This evidence concerns the gene BCL2 and acute myeloid leukemia.